Zai Lab FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Zai Lab in a research report issued on Tuesday, July 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.95) per share for the year, down from their prior estimate of ($0.94). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab’s FY2026 earnings at $0.30 EPS.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The company had revenue of $106.49 million during the quarter, compared to the consensus estimate of $118.40 million.

A number of other equities research analysts also recently weighed in on the company. Scotiabank initiated coverage on Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, March 13th. Wall Street Zen cut shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Friday, June 27th. Finally, Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an “outperform” rating in a report on Monday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $54.28.

Zai Lab Stock Up 2.6%

Shares of NASDAQ ZLAB opened at $36.43 on Thursday. The stock’s 50 day moving average price is $33.71 and its two-hundred day moving average price is $31.32. Zai Lab has a 52-week low of $16.01 and a 52-week high of $44.34. The stock has a market capitalization of $4.05 billion, a P/E ratio of -14.63 and a beta of 0.99.

Hedge Funds Weigh In On Zai Lab

Several hedge funds and other institutional investors have recently made changes to their positions in ZLAB. GF Fund Management CO. LTD. bought a new stake in Zai Lab during the 4th quarter valued at $29,000. Pictet Asset Management Holding SA acquired a new position in shares of Zai Lab during the fourth quarter valued at $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab during the first quarter valued at about $75,000. Advisors Preferred LLC acquired a new stake in Zai Lab in the first quarter worth about $110,000. Finally, Barclays PLC grew its position in Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after buying an additional 2,856 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 13,814 shares of the business’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the transaction, the director directly owned 35,106 shares of the company’s stock, valued at $1,252,231.02. The trade was a 28.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Yajing Chen sold 9,618 shares of the company’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00. Following the completion of the transaction, the chief financial officer owned 17,429 shares of the company’s stock, valued at approximately $522,870. This trade represents a 35.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 160,155 shares of company stock worth $4,959,535 in the last three months. 4.96% of the stock is owned by insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.